Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Medicale (MCLE) EPS (Weighted Average and Diluted) (2021 - 2025)

Medicale's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.0 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.0; the TTM value through Jun 2025 reached -$0.0, changed N/A, while the annual FY2023 figure was $0.0, 118.96% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.0 in Q2 2025 per MCLE's latest filing, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q4 2022 to a low of -$0.0 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.0, with a median of -$0.0 recorded in 2021.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 175.83% in 2022 against a maximum downside of 93.37% in 2022.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2021, then surged by 175.83% to $0.0 in 2022, then plummeted by 3395.6% to -$0.0 in 2024, then skyrocketed by 76.16% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for MCLE's EPS (Weighted Average and Diluted) are -$0.0 (Q2 2025), -$0.0 (Q1 2025), and -$0.0 (Q4 2024).